Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Expert Insight on Key Data From SGO 2022 Informing Treatment for Endometrial, Ovarian, and Cervical Cancers

2022; SGO, March; ASCO, June, ESMO, September; IGCS September; ESGO, October
In this podcast episode, listen to David Scott Miller, MD, FACOG, FACS, and Angeles Alvarez Secord, MD, MHSc, discuss key data for gynecologic cancers presented at the 2022 SGO annual meeting, including data for novel agents in ovarian and endometrial cancers, and practical insights on recent approvals for cervical cancer.
David Scott Miller, MD, FACOG, FACS
Angeles Alvarez Secord, MD, MHSc
Released: May 19, 2022

In this episode, David Scott Miller, MD, FACOG, FACS, and Angeles Alvarez Secord, MD, MHSc, provide expert insights on key data presented at SGO 2022 for ovarian, endometrial, and cervical cancers regarding:

  • Results from the prospective phase III PRIME study of an individualized dose for niraparib vs placebo maintenance in newly diagnosed advanced ovarian cancer
  • Final OS analysis from phase III SOLO-3 evaluating olaparib vs physician’s choice of single-agent nonplatinum chemotherapy in gBRCAm platinum-sensitive relapsed ovarian cancer
  • Results from the phase III SORAYA trial of mirvetuximab soravtansine, an FRα-targeting ADC with a potent tubulin-targeting maytansinoid (DM4) delivered to tumor cells, in patients with platinum-resistant ovarian cancer who had recurrence within 6 months after last platinum dose and had 1-3 prior treatments
  • Results from the randomized, double-blind, placebo-controlled phase III trial of selinexor vs placebo as maintenance in patients with stage IV endometrial cancer who had a PR/CR on ≥12 weeks of first-line taxane/carboplatin
  • The results from a cost-effectiveness analysis for the addition of pembrolizumab to chemotherapy with or without bevacizumab in patients with persistent, recurrent, or metastatic cervical cancer

Information on this Educational Activity

Faculty

David Scott Miller, MD, FACOG, FACS

Amy and Vernon E. Faulconer Distinguished Chair in Medical Science
Director and Dallas Foundation Chair in Gynecologic Oncology
Professor of Obstetrics & Gynecology
Fred F. Florence Bioinformation Center
University of Texas Southwestern Medical Center
Medical Director of Gynecologic Oncology
Chair,
Cancer Committee
Parkland Health & Hospital System
Dallas, Texas

David Scott Miller, MD, FACOG, FACS, has disclosed that he has received funds for research support from Advenchen, Agenus, Akesobio, EMD Serono, Karyopharm, Merck Sharpe & Dohme, Novocure, and Tesaro and consulting fees from AbbVie, AstraZeneca, Eisai, Eisai Europe, EMD Serono, Incyte, iTeso Belgium, GlaxoSmithKline, Myriad, Novocure, Seagen, Tarveda, and Tesaro.
Angeles Alvarez Secord, MD, MHSc

Professor
Division of Gynecologic Oncology
Department of OB/GYN
Duke Cancer Institute
Duke University Health System
Durham, North Carolina

Angeles Alvarez Secord, MD, MHSc, has disclosed that she has received consulting fees from Eisai and Myriad and funds for research support from AbbVie, AstraZeneca, Boehringer Ingelheim, Clovis, Eisai, Immutep, Merck, OncoQuest, PharmaMar, Roche/Genentech, Seagen, Tesaro/GlaxoSmithKline, and VBL.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
GlaxoSmithKline
Karyopharm Therapeutics
Merck Sharp & Dohme Corp.

Related Content

Final OS data for PAOLA-1 phase III trial of maintenance olaparib plus bevacizumab vs placebo plus bevacizumab in newly diagnosed ovarian cancer, presented at ESMO 2022 and reported by Clinical Care Options (CCO)

Released: September 27, 2022

Downloadable slideset updated with highlights of key gynecologic oncology studies presented at conferences throughout 2022, from Clinical Care Options (CCO)

Jubilee Brown, MD person default Elisabeth Diver, MD person default Alexandra Leary, MD, PhD Domenica Lorusso, MD, PhD David Scott Miller, MD, FACOG, FACS Angeles Alvarez Secord, MD, MHSc Released: September 26, 2022

7-year follow-up from phase III SOLO-1 trial of maintenance olaparib vs placebo in newly diagnosed advanced ovarian cancer, presented at ESMO 2022 and reported by Clinical Care Options (CCO)

Released: September 15, 2022

Interactive online tool with expert management recommendations for selecting therapy for women with advanced endometrial cancer, from Clinical Care Options (CCO)

Maria Bell, MD, MPH, MBA Hye Sook Chon, MD Linda R. Duska, MD, MPH Ritu Salani, MD, MBA Shannon N. Westin, MD, MPH Released: September 13, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings